A Hands-On, High Touch Approach

One project at a time, we're changing the way University faculty view their work—at the same time, we're realizing Wallace Coulter’s goal of “science serving humanity.”

The UVA-Coulter Translational Research Partnership awards $700,000 each year to biomedical engineering faculty members and research collaborators from the School of Medicine, the School of Engineering and other areas of the University. Together, teams of co-investigators work to develop new technologies that address unmet clinical needs, improve health care and lead to commercially available products.

In the process of funding scores of projects over the last decade, UVA-Coulter has stimulated a culture of translational research at the University,

Our Mission

The mission of the UVA-Coulter Translational Partnership is to support research projects that are explicitly translational in nature and in the doing so, develop and validate models of translational that can be widely adopted.

In the early 2000s, the Wallace H. Coulter Foundation conceived a grand experiment to link the relatively new discipline of biomedical engineering to translational research. The University of Virginia was one of ten original institutions selected for a Coulter Translational Research Partnership Award.

History and Timeline

  • The grand experiment begins


    The Wallace H. Coulter Foundation announces that the University of Virginia is one of 10 universities that will form the first phase of the Coulter Translational Partnership program. The foundation provides UVA $5.9 million duiring this five year period.

  • UVA funds its first projects


    The UVA-Coulter Partnership makes its first awards. These include the use of adipose stem cells for chronic wound healing and the real-time cardiac stress testing.

  • $20M endowment


    The University of Virginia teams with the Coulter Foundation to create a $20 million endowment to foster collaboration between biomedical engineers and clinicians leading to new technologies to improve patient care and human health.

  • first technology is licensed

    First UVA-Coulter-supported technology is licensed.

  • first start-up company

    XXX becomes the first start-up company based on UVA-Coulter supported technology. It is commercializing a xxx that does xxx and yyy.

  • our biggest exit


    UVA-Coulter start-up HemoShear enters into an agreement with Takeda Pharmaceutical Company that could be worth as much as $470 million. The two companies will use HemoShear’s proprietary disease modeling platform to discover and develop novel therapeutics for liver diseases.

Coulter Team

Translational research is a priority of UVA’s Department of Biomedical Engineering. Over the years, the UVA-Coulter Translational Partnership has developed a highly articulated and customizable system of shepherding research projects across the gap between laboratory and marketplace.

Leadership Team

  • David Chen, MS, MBA

    Founding Program Director

    David Chen began his career at ImClone Systems, where he worked closely with both European regulatory agencies as well as the FDA. He holds a Master of Science in Cell and Developmental Biology from Rutgers University/Robert Wood Johnson Medical School and an MBA from UVA’s Darden School of Business. Email David Chen.

    Faculty Profile
  • Frederick Epstein, PhD

    Principal Investigator and Department Chair

    Frederick Epstein develops magnetic resonance imaging (MRI) techniques for assessing the structure, function and perfusion of the cardiovascular system, particularly in the setting of cardiovascular disease, diabetes and musculoskeletal disease. Email Fred Epstein.

    Faculty Profile
  • Hannah Moore

    Hannah Moore

    Coulter Program Administrator

    Hannah Moore facilitates approvals and permissions for current funded projects and also works closely with faculty members during the proposal process to ensure they have all the information needed to receive funding and launch their projects.  She has a clinical background in endocrinology, rheumatology and primary care. Email Hannah Moore.

Our University Partners

These on-Grounds partners are helping to ensure that promising technologies developed by its faculty enter the marketplace, where they can benefit citizens of the Commonwealth, the nation and the world.

  • UVA Licensing and Ventures Group

    The LVG reviews proposals for the UVA-Coulter Oversight Committee and provides input to Coulter researchers as well as connections to industry partners who can help shape the development of their intellectual property.

  • UVA Licensing and Venture Group Seed Fund

    UVA's $10 million Seed Fund managed by the Licensing and Ventures Group has invested in a number of start-ups based on innovations developed with Coulter funding.

    LVG Seed Fund
  • UVA's Offices of Research

    School of Engineering | School of Medicine

    The UVA-Coulter Program coordinates with the Offices of Research in the School of Engineering and Applied Science and the School of Medicine to secure support and funding for Coulter researchers.